The Latest Breaking News from ORIC

Billionaire investor Steve Cohen invested over $100 million in two biopharma stocks, one of which has rallied over 90% in the past one month.

ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.

A subsidiary of Balanggarra Aboriginal Corporation runs one of the East Kimberley's prized tourism assets, Home Valley. However a series of failed annual general meetings have increased tension among members and sparked calls for more transparency.

Last year, an investigation uncovered serious concerns with the governance of RivMed and its board was ousted. Six months later, there's hope the corporation has turned over a new leaf.

Alcohol treatment services in the Northern Territory are facing having to cut staff looking after vulnerable Indigenous clients because they're being squeezed between rising costs and stagnant government funding, their peak body is warning.

Campaigners say utility firm’s investment plan to remedy situation is ‘completely inadequate’

ORIC Pharmaceuticals Inc (NASDAQ:ORIC) has decided to discontinue the further development of ORIC-101 after interim analyses from the two Phase 1b studies, wherein ORIC-101 did not demonstrate sufficient clinical activity. The dose-expansion portion of the Phase 1b trial of ORIC-101 combined with enzalutamide enrolled 28 patients at the recommended phase 2 dose (RP2D)…

Authorities are investigating the former chief executive of an important Northern Territory alcohol rehabilitation service for allegedly misusing its resources and bullying an employee. She denies the allegations.